8-K: Ginkgo Bioworks Reports 27% Revenue Increase in Q1 2025, Driven by Restructuring and Biopharma Growth

Ginkgo Bioworks announced a 27% increase in total revenue for Q1 2025, driven by restructuring efforts and growth in biopharma and government sectors, along with an expanded cost savings target of $250 million.

Summary

• Ginkgo Bioworks reported its financial results for the first quarter ended March 31, 2025.
• Total revenue for Q1 2025 was $48 million, a 27% increase compared to $38 million in the same period last year.
• Excluding a $7 million non-cash revenue release, total revenue was $41 million, an 8% increase year-over-year.
• Cell Engineering revenue increased by 10% to $31 million, driven by growth with biopharma and government customers.
• Biosecurity revenue remained flat at $10 million.
• GAAP net loss was $(91) million, an improvement from $(166) million in the prior year period.
• Adjusted EBITDA was $(47) million, up from $(117) million in the prior year period.
• The company's cash, cash equivalents, and marketable securities balance was $517 million as of March 31, 2025.
• Ginkgo is targeting $250 million in cost reductions by the end of Q3 2025, having already achieved an annualized run-rate cost reduction of $205 million.
• Full year 2025 revenue guidance is updated to $167-$187 million, with Cell Engineering revenue expected to be $117-$137 million and Biosecurity revenue at least $50 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth, improved profitability metrics, and progress on cost reduction. However, the company is still operating at a loss and faces risks related to government funding and market volatility.

Positives

• Total revenue increased by 27% in Q1 2025, indicating growth in the business.
• Cell Engineering revenue grew by 10%, showing strength in this segment.
• Net loss and Adjusted EBITDA improved significantly compared to the prior year, reflecting better financial performance.
• The company is making progress on cost reduction targets, which will improve profitability.
• Ginkgo has a strong cash position with $517 million in cash, cash equivalents, and marketable securities.
• The company secured a $29 million contract with ARPA-H, demonstrating its capabilities and market position.
• Ginkgo has 28 US Government projects across Cell Engineering and Biosecurity with ~$180M of contracted backlog and unfunded potential backlog.

Negatives

• The company still reported a GAAP net loss of $(91) million, indicating ongoing losses.
• Biosecurity revenue remained flat, suggesting a lack of growth in this segment.
• Adjusted EBITDA is still negative at $(47) million, although improved from the prior year.
• The company's cash balance decreased from $561.6 million at the end of 2024 to $312.4 million as of March 31, 2025.

Risks

• The company's ability to achieve Adjusted EBITDA breakeven by the end of 2026 is subject to risks and uncertainties.
• The company's reliance on government funding and contracts could be impacted by changes in government budgetary priorities.
• The company faces risks related to the volatility and liquidity of holding equity interests in other operating companies.
• The company's ability to realize cost savings from site consolidation plans is subject to risks.
• The company's future performance is subject to various risks and uncertainties outlined in its SEC filings.

Future Outlook

Ginkgo updated its full year 2025 revenue guidance to $167-$187 million, with Cell Engineering revenue expected to be $117-$137 million and Biosecurity revenue at least $50 million. The company aims to achieve Adjusted EBITDA breakeven by the end of 2026.

Management Comments

• Jason Kelly, co-founder and CEO of Ginkgo Bioworks, stated that the company is starting the year on a solid base due to restructuring efforts.
• Jason Kelly noted that the Solutions business has become a trusted R&D service provider to the US Government and biopharma industry.
• Jason Kelly mentioned that the Tools businesses have traction and are positioned to meet emergent opportunities in areas like AI.
• Jason Kelly emphasized the company's commitment to achieving its cost reduction targets.

Industry Context

The announcement highlights the growing importance of biotechnology in the US, with Ginkgo positioned to capitalize on opportunities in biosecurity and R&D services. The company's focus on AI and large-scale biological datasets aligns with industry trends.

Comparison to Industry Standards

• It's difficult to directly compare Ginkgo's results to industry standards due to its unique platform approach.
• However, comparable companies in the synthetic biology space include Amyris and Zymergen (now acquired).
• Amyris, before its restructuring, focused on producing sustainable ingredients, while Zymergen aimed to create novel materials.
• Ginkgo's revenue growth and cost reduction efforts are key metrics to watch compared to these peers.
• The $29 million ARPA-H contract is a significant win, demonstrating Ginkgo's competitive position in securing government funding for biosecurity and R&D projects.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth and improved profitability metrics.
• Employees may be impacted by ongoing cost reduction efforts and restructuring.
• Customers will benefit from Ginkgo's continued investment in its platform and services.
• Suppliers may be affected by the company's cost reduction initiatives.
• Creditors will be reassured by the company's strong cash position and improved financial performance.

Next Steps

• Ginkgo will host a videoconference on May 6, 2025, to discuss the first quarter results.
• The company will continue to focus on achieving its cost reduction targets by the end of Q3 2025.
• Ginkgo will work towards achieving Adjusted EBITDA breakeven by the end of 2026.

Key Dates

Keywords

Ginkgo Bioworks, Financial Results, Q1 2025, Revenue, Cell Engineering, Biosecurity, Adjusted EBITDA, Cost Savings, Guidance, Synthetic Biology